Paterson D Ian, Wiebe Natasha, Cheung Winson Y, Mackey John R, Pituskin Edith, Reiman Anthony, Tonelli Marcello
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
JACC CardioOncol. 2022 Mar 15;4(1):85-94. doi: 10.1016/j.jaccao.2022.01.100. eCollection 2022 Mar.
Patients with cancer and cancer survivors are at increased risk for incident heart failure, but there are conflicting data on the long-term risk for other cardiovascular events and how such risk may vary by cancer site.
The aim of this study was to determine the impact of a new cancer diagnosis on the risk for fatal and nonfatal cardiovascular events.
Using administrative health care databases, a population-based retrospective cohort study was conducted among 4,519,243 adults residing in Alberta, Canada, from April 2007 to December 2018. Participants with new cancer diagnoses during the study period were compared with those without cancer with respect to risk for subsequent cardiovascular events (cardiovascular mortality, myocardial infarction, stroke, heart failure, and pulmonary embolism) using time-to-event survival models after adjusting for sociodemographic data and comorbidities.
A total of 224,016 participants with new cancer diagnoses were identified, as well as 73,360 cardiovascular deaths and 470,481 nonfatal cardiovascular events during a median follow-up period of 11.8 years. After adjustment, participants with cancer had HRs of 1.33 (95% CI: 1.29-1.37) for cardiovascular mortality, 1.01 (95% CI: 0.97-1.05) for myocardial infarction, 1.44 (95% CI: 1.41-1.47) for stroke, 1.62 (95% CI: 1.59-1.65) for heart failure, and 3.43 (95% CI: 3.37-3.50) for pulmonary embolism, compared with participants without cancer. Cardiovascular risk was highest for patients with genitourinary, gastrointestinal, thoracic, nervous system and hematologic malignancies.
A new cancer diagnosis is independently associated with a significantly increased risk for cardiovascular death and nonfatal morbidity regardless of cancer site. These findings highlight the need for a collaborative approach to health care for patients with cancer and cancer survivors.
癌症患者及癌症幸存者发生心力衰竭的风险增加,但关于其他心血管事件的长期风险以及该风险如何因癌症部位而异的数据存在矛盾。
本研究的目的是确定新发癌症诊断对致命和非致命心血管事件风险的影响。
利用行政医疗保健数据库,于2007年4月至2018年12月在加拿大艾伯塔省居住的4519243名成年人中进行了一项基于人群的回顾性队列研究。在调整社会人口统计学数据和合并症后,使用事件发生时间生存模型,比较研究期间新发癌症诊断的参与者与无癌症参与者发生后续心血管事件(心血管死亡、心肌梗死、中风、心力衰竭和肺栓塞)的风险。
共识别出224016名新发癌症诊断的参与者,并在中位随访期11.8年期间发生了73360例心血管死亡和470481例非致命心血管事件。调整后,与无癌症参与者相比,癌症患者发生心血管死亡的风险比(HR)为1.33(95%置信区间:1.29 - 1.37),心肌梗死为1.01(95%置信区间:0.97 - 1.05),中风为1.44(95%置信区间:1.41 - 1.47),心力衰竭为1.62(95%置信区间:1.59 - 1.65),肺栓塞为3.43(95%置信区间:3.37 - 3.50)。泌尿生殖系统、胃肠道、胸部、神经系统和血液系统恶性肿瘤患者的心血管风险最高。
无论癌症部位如何,新发癌症诊断均与心血管死亡和非致命发病风险显著增加独立相关。这些发现凸显了对癌症患者和癌症幸存者采取协作性医疗保健方法的必要性。